You are leaving the Blue Earth Diagnostics website. By clicking this link, you will be taken to a website that is independent from Blue Earth Diagnostics. The site you are linking to is not controlled or endorsed by Blue Earth Diagnostics and Blue Earth Diagnostics is not responsible for the content provided on that site.

ACCEPT CANCEL

Blue Earth Diagnostics News

+44 (0)1865 784 186

contact@blueearthDx.com

These media releases are intended for business/trade media.

2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2022

NEWS FROM

27, September, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting
READ MORE
26, September, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces CMS Transitional Pass-Through Payment Reimbursement Code for POSLUMA® (Flotufolastat F 18) Injection, Effective October 1, 2023
READ MORE
25, July, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Addition of POSLUMA® (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer
READ MORE
27, June, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 LIGHTHOUSE Trial of POSLUMA® (Flotufolastat F18) Injection in Newly Diagnosed Prostate Cancer
READ MORE
26, June, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Results of Post-hoc Analysis Assessing Impact of Urinary Activity on Interpretation of POSLUMA® (Flotufolastat F 18) Injection PET/CT in Prostate Cancer
READ MORE
21, June, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA® (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer
READ MORE
20, June, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights POSLUMA® (Flotufolastat F 18) Injection and Investigational 18F-Flotufolastat Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
READ MORE
30, May, 2023
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
READ MORE
29, April, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer − Results at the American Urological Association’s 2023 Annual Meeting (AUA2023)
READ MORE
16, February, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Additional Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer
READ MORE
09, February, 2023
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer
READ MORE

NEWS FROM

01, December, 2022
Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer
READ MORE
22, November, 2022
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming RSNA® 2022 Annual Meeting
READ MORE
21, November, 2022
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Upcoming Presentation of Results from Phase 3 LIGHTHOUSE Study of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer
READ MORE
24, October, 2022
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
READ MORE
19, October, 2021
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine (18F)) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer at Upcoming ASTRO Annual Meeting
READ MORE
18, October, 2022
Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3, to support AI-based Algorithms Development
READ MORE
27, September, 2022
Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer
READ MORE
19, July, 2022
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Independent Clinical Studies Published Regarding Performance of Axumin® (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)
READ MORE
15, June, 2022
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
READ MORE
09, June, 2022
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Presentations on Investigational rhPSMA Radiopharmaceuticals and 18F-Fluciclovine at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
READ MORE
08, June, 2022
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
READ MORE
13, May, 2022
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
READ MORE
05, May, 2022
THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer
READ MORE
28, February, 2022
Blue Earth Diagnostics Appoints Dr. David E. Gauden as Chief Executive Officer and Dr. Eugene J. Teoh as Chief Medical Officer
READ MORE
15, February, 2022
Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer
READ MORE
01, February, 2022
Blue Earth Diagnostics Highlights Upcoming Presentation of Key Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F‐rhPSMA‐7.3 in Biochemically Recurrent Prostate Cancer
READ MORE

NEWS FROM 2021

30, November, 2021
Blue Earth Diagnostics Highlights Axumin® (Fluciclovine F18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)
READ MORE
19, October, 2021
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting
READ MORE
27, September, 2021
Blue Earth Diagnostics Announces Results of an Analysis of the Impact of Axumin® (Fluciclovine F 18) PET/CT Imaging on Androgen Deprivation Therapy (ADT) Planning in Recurrent Prostate Cancer
READ MORE
15, September, 2021
Blue Earth Diagnostics Supports Timely Consideration and Passage of the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 by U.S. Congress.
READ MORE
08, September, 2021
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming American Urological Association’s 2021 Annual Meeting
READ MORE
10, August, 2021
Blue Earth Diagnostics Announces Upcoming 18F-Fluciclovine Presentations at 2021 Society of Neuro-Oncology (SNO) Conference on Brain Metastases
READ MORE
08, June, 2021
Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
READ MORE
02, June, 2021
Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) Presentations at Upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
READ MORE
25, May, 2021
The Lancet Publishes Results of Axumin® (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer
READ MORE
08, February, 2021
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming 2021 ASCO Genitourinary Cancers Symposium (ASCO GU)
READ MORE
12, January, 2021
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
READ MORE
05, January, 2021
Blue Earth Diagnostics Acquires Exclusive, Worldwide Rights to Therapeutic Applications of Scintomics’ Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) Technology for Prostate Cancer
READ MORE

NEWS FROM 2020

24, November, 2020
Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent rhPSMA-7.3 (18F) in Collaboration with Nucleis Radiopharmaceuticals in Liege, Belgium
READ MORE
20, October, 2020
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting
READ MORE
01, July, 2020
Blue Earth Diagnostics Announces Dosing of Initial Patients in Phase 3 SPOTLIGHT Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Biochemically Recurrent Prostate Cancer
READ MORE
16, June, 2020
Blue Earth Diagnostics and PETNET Solutions Announce New Commercial Supply Agreement for Axumin® (Fluciclovine F 18) and Investigational rhPSMA-7.3 (18F) Prostate Cancer Imaging Agent
READ MORE
18, May, 2020
Blue Earth Diagnostics Announces Results from Early Clinical Experience with Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Men with Intermediate and High-risk Prostate Cancer
READ MORE
01, May, 2020
Blue Earth Diagnostics CEO Jonathan Allis Appointed Chair of UK Rapid Testing Consortium (UK-RTC) for COVID-19 by UK Department of Health and Social Care
READ MORE
21, April, 2020
Blue Earth Diagnostics continues to expand access to Axumin® (fluciclovine (18F)) with first commercial supply in Slovakia, Europe
READ MORE
17, March, 2020
Blue Earth Diagnostics Announces Dosing of First Patient in Phase 3 LIGHTHOUSE Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Newly Diagnosed Prostate Cancer
READ MORE
11, February, 2020
Blue Earth Diagnostics Announces Upcoming Presentations from FALCON Study of Axumin® (Fluciclovine F18) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer
READ MORE

NEWS FROM 2019

16, September, 2019
Results from Blue Earth Diagnostics’ FALCON Trial Show 64% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Following Axumin® (Fluciclovine F 18) PET/CT Scan
READ MORE
10, September, 2019
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming ASTRO Annual Meeting
READ MORE
01, August, 2019
Bracco Imaging announces completion of acquisition of Blue Earth Diagnostics
READ MORE
27, June, 2019
Blue Earth Diagnostics Announces Highlights of Technical University of Munich Presentations on Initial Clinical Experience with 18F-rhPSMA-7 PET Imaging in High Risk Primary and Biochemical Recurrent Prostate Cancer
READ MORE
26, June, 2019
Blue Earth Diagnostics to be Acquired by Global Leader Bracco Imaging
READ MORE
26, June, 2019
Blue Earth Diagnostics Announces Results from Investigational Clinical Study of Safety and Effectiveness of 18F-Fluciclovine PET Imaging in Adult Glioma
READ MORE
12, June, 2019
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
READ MORE
09, May, 2019
Blue Earth Diagnostics continues to expand access to Axumin® (fluciclovine (18F)) in Europe
READ MORE
06, May, 2019
Blue Earth Diagnostics Announces Results of Additional Analyses from LOCATE Trial Evaluating Change in Recurrent Prostate Cancer Management Following Axumin® (Fluciclovine F 18) PET/CT Imaging
READ MORE
06, May, 2019
Blue Earth Diagnostics Announces Results from Initial Clinical Experience of 18F-rhPSMA-7 PET Imaging in High-risk Primary and Biochemical Recurrent Prostate Cancer by Technical University of Munich
READ MORE
24, April, 2019
Blue Earth Diagnostics Announces Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming American Urological Association’s 2019 Annual Meeting
READ MORE
16, April, 2019
Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer
READ MORE
06, March, 2019
Blue Earth Diagnostics celebrates five year anniversary
READ MORE
12, February, 2019
First production and administration of Axumin® (fluciclovine (18F)) in Italy.
READ MORE
06, February, 2019
Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) LOCATE Study Presentation at Upcoming ASCO 2019 Genitourinary Cancers Symposium on Impact on Clinical Management of Recurrent Prostate Cancer
READ MORE

NEWS FROM 2018

12, December, 2018
First production and administration of Axumin® (fluciclovine (18F)) in France.
READ MORE
10, December, 2018
Blue Earth Diagnostics Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of Supplemental New Drug Application (sNDA) for 18F-fluciclovine PET Imaging in Glioma
READ MORE
19, November, 2018
Blue Earth Diagnostics Announces Results of Investigational Phase 3 Blinded Image Evaluation Study of 18F-Fluciclovine PET Imaging in Glioma
READ MORE
14, November, 2018
Blue Earth Diagnostics Announces 18F-Fluciclovine Research Presentation at Upcoming Society for Neuro-Oncology (SNO) Annual Scientific Meeting
READ MORE
17, October, 2018
Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming ASTRO Annual Meeting
READ MORE
12, October, 2018
Blue Earth Diagnostics wins prestigious “Best Emerging Biotech” award
READ MORE
02, October, 2018
Axumin® (fluciclovine (18F)) receives positive recommendation from Transparency Committee of the French HAS, for use in PET imaging of suspected recurrent prostate cancer
READ MORE
11, September, 2018
The Journal of Urology Publishes Results from Blue Earth Diagnostics’ LOCATE Trial of Role of 18F Fluciclovine PET/CT Imaging in the Management of Men with Recurrent Prostate Cancer
READ MORE
09, August, 2018
Blue Earth Diagnostics shortlisted for prestigious “Best Emerging Biotech Company” award
READ MORE
25, June, 2018
Blue Earth Diagnostics appoints IASON Sp. z o.o. to manufacture and distribute Axumin® (fluciclovine (18F)) in Poland
READ MORE
18, June, 2018
Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
READ MORE
21, May, 2018
Results from Blue Earth Diagnostics’ LOCATE Trial Show 59% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Plan Following 18F Fluciclovine PET/CT Scan
READ MORE
14, May, 2018
Blue Earth Diagnostics Announces Presentation on Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer at Upcoming AUA2018, Annual Meeting of the American Urological Association
READ MORE
02, May, 2018
Blue Earth Diagnostics Expands Oncology Portfolio with Exclusive, Worldwide Licensing of Investigational Radiohybrid PSMA-targeted Agents for Prostate Cancer from Scintomics
READ MORE
12, April, 2018
Blue Earth Diagnostics opens new headquarters in Oxford
READ MORE
20, February, 2018
Blue Earth Diagnostics Announces Addition of Axumin® (Fluciclovine F 18) to NCCN Guidelines® for PET Imaging for Suspected Recurrent Prostate Cancer
READ MORE
06, February, 2018
Blue Earth Diagnostics Announces Presentation at Upcoming ASCO 2018 Genitourinary Cancers Symposium on Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer
READ MORE

NEWS FROM 2017

10, October, 2017
Blue Earth Diagnostics and Seibersdorf Laboratories Announce Manufacturing and Distribution Agreements for Axumin® (fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer
READ MORE
02, October, 2017
Blue Earth Diagnostics and GE Healthcare sign UK manufacturing agreement
READ MORE
06, September, 2017
Blue Earth Diagnostics Announces Late-Breaking Initial Results of Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer at Upcoming ASTRO Annual Meeting
READ MORE
30, August, 2017
Blue Earth Diagnostics Named as Finalist in First Annual Xconomy Awards
READ MORE
11, August, 2017
Blue Earth Diagnostics shortlisted for “Best Emerging Medtech Company” award
READ MORE
27, July, 2017
Blue Earth Diagnostics appoints M2i to manufacture and distribute Axumin™ in Ireland
READ MORE
28, June, 2017
Blue Earth Diagnostics joins the British Institute of Radiology
READ MORE
23, May, 2017
Blue Earth Diagnostics receives marketing authorisation for Axumin™ (Fluciclovine (18F)) for PET imaging of recurrent prostate cancer
READ MORE
22, May, 2017
Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer
READ MORE
12, May, 2017
Blue Earth Diagnostics’ FALCON Trial of Fluciclovine (18F) PET/CT Imaging in Recurrent Prostate Cancer Stops Recruitment after Successful Interim Analysis
READ MORE
03, May, 2017
Blue Earth Diagnostics Announces Publication of Reader Training Study Results for AxuminTM (Fluciclovine F 18) PET Imaging of Men with Recurrent Prostate Cancer
READ MORE
24, March, 2017
Blue Earth Diagnostics receives positive CHMP opinion for Axumin™ (Fluciclovine (18F)) for PET imaging of recurrent prostate cancer
READ MORE
07, February, 2017
Blue Earth Diagnostics and Siemens’ PETNET Solutions Increase Patient Access to Axumin™ (Fluciclovine F 18) Injection PET Imaging Agent for Suspected Recurrent Prostate Cancer
READ MORE

NEWS FROM 2016

29, November, 2016
Blue Earth Diagnostics and Northern California PET Imaging Center Announce Region’s First Commercial AxuminTM (Fluciclovine F 18) Administration
READ MORE
25, October, 2016
The Journal of Urology Publishes Blue Earth Diagnostics’ Phase 3 Study Results of AxuminTM (Fluciclovine F 18) for PET Imaging of Recurrent Prostate Cancer
READ MORE
08, September, 2016
Blue Earth Diagnostics Announces First Commercial Administrations of AxuminTM (Fluciclovine F 18) by Atlanta’s Northside Hospital
READ MORE
08, September, 2016
Blue Earth Diagnostics Announces AxuminTM (Fluciclovine F 18) Presentations at Upcoming Scientific Conferences
READ MORE
10, June, 2016
Blue Earth Diagnostics and Siemens’ PETNET Solutions Announce Commercial Availability of AxuminTM (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer
READ MORE
09, June, 2016
Blue Earth Diagnostics Announces AxuminTM (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
READ MORE
03, June, 2016
FDA approves new diagnostic imaging agent to detect recurrent prostate cancer
READ MORE
03, June, 2016
U.S. FDA Approves Blue Earth Diagnostics’ AxuminTM (Fluciclovine F 18) Injection after Priority Review for PET Imaging of Recurrent Prostate Cancer
READ MORE
13, May, 2016
Blue Earth Diagnostics Announces Opening of U.S. Office and Expansion of Management Team
READ MORE
31, March, 2016
Blue Earth Diagnostics begins fluciclovine (18F) studies in Recurrent Prostate Cancer Patients
READ MORE
24, March, 2016
Blue Earth Diagnostics and Norsk medisinsk syklotronsenter AS announce manufacturing and distribution partnership for Fluciclovine (18F)
READ MORE

NEWS FROM

19, October, 2021
Description event
READ MORE
European Conferences

2022

European Conferences

VIEW MORE
U.S. Conferences

2022

U.S. Conferences

VIEW MORE

© 2021 Blue Earth Diagnostics All rights reserved.